サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：インフルエンザ迅速診断検査 (RIDT) の世界市場 (2022-2030年)：市場予測 (エンドユーザー (病院・診断センター・研究ラボ) 別)・地域的展望・用途の潜在性・価格動向・市場シェア
市場調査レポート
商品コード
1081233

インフルエンザ迅速診断検査 (RIDT) の世界市場 (2022-2030年)：市場予測 (エンドユーザー (病院・診断センター・研究ラボ) 別)・地域的展望・用途の潜在性・価格動向・市場シェア

Rapid Influenza Diagnostic Tests (RIDT) Market Size by End-use (Hospitals, Diagnostics Centers, Research Laboratories), Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2022 - 2030
出版日: | 発行: Global Market Insights Inc. | ページ情報: 英文 80 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.53円
インフルエンザ迅速診断検査 (RIDT) の世界市場 (2022-2030年)：市場予測 (エンドユーザー (病院・診断センター・研究ラボ) 別)・地域的展望・用途の潜在性・価格動向・市場シェア
出版日: 2022年05月11日
発行: Global Market Insights Inc.
ページ情報: 英文 80 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

インフルエンザ迅速診断検査 (RIDT) の市場は、インフルエンザの流行が拡大していることから、2030年にかけて大きく成長すると予想されています。

また、早期診断の必要性の高まりや、迅速検査の普及も、予測期間中の市場成長をさらに押し上げると考えられています。

エンドユーザー別で見ると、病院の部門が2021年に2億7,200万米ドルを超える収益規模を示し、2030年にかけても大きな成長を示す見通しです。

当レポートでは、世界のインフルエンザ迅速診断検査 (RIDT) の市場を調査し、市場の定義と概要、新型コロナウイルス感染症 (COVID-19) およびその他の市場影響因子の分析、法規制環境、技術・イノベーションの情勢、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

第3章 インフルエンザ迅速診断検査 (RIDT) 産業の考察

  • 産業の分類
  • 産業情勢
  • 産業への影響要因
    • 成長要因
    • 潜在的リスク＆課題
  • 成長の可能性の分析
  • COVID-19：影響分析
  • ポーターの分析
  • 競合情勢
  • PESTEL分析

第4章 インフルエンザ迅速診断検査 (RIDT) 市場：エンドユーザー別

  • 主要動向
  • 病院
  • 診断センター
  • 研究ラボ
  • その他

第5章 インフルエンザ迅速診断検査 (RIDT) 市場：地域別

  • 主要動向
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ

第6章 企業プロファイル

  • 競合ダッシュボード
  • F. Hoffmann-La Roche Ltd
  • Abbott
  • Becton, Dickinson and Company
  • Coris BioConcept
  • DiaSorin SpA
  • Meridian Bioscience Inc.
  • Quidel Corporation
  • Sekisui Diagnostics
  • Thermo Fischer Scientific Inc.
  • Hologic Inc.
図表

Data Tables

  • TABLE 1. Global rapid influenza diagnostic tests market, 2017 - 2021 (USD Million)
  • TABLE 2. Global rapid influenza diagnostic tests market, 2022 - 2030 (USD Million)
  • TABLE 3. Global rapid influenza diagnostic tests market, by end-use, 2017 - 2021 (USD Million)
  • TABLE 4. Global rapid influenza diagnostic tests market, by end-use, 2022 - 2030 (USD Million)
  • TABLE 5. Global rapid influenza diagnostic tests market, by region, 2017 - 2021 (USD Million)
  • TABLE 6. Global rapid influenza diagnostic tests market, by region, 2022 - 2030 (USD Million)
  • TABLE 7. Industry impact forces
  • TABLE 8. Hospitals market size, by region, 2017 - 2021 (USD Million)
  • TABLE 9. Hospitals market size, by region, 2022 - 2030 (USD Million)
  • TABLE 10. Diagnostics centers market size, by region, 2017- 2021 (USD Million)
  • TABLE 11. Diagnostics centers market size, by region, 2022 - 2030 (USD Million)
  • TABLE 12. Research laboratories market size, by region, 2017 - 2021 (USD Million)
  • TABLE 13. Research laboratories market size, by region, 2022 - 2030 (USD Million)
  • TABLE 14. Others market size, by region, 2017 - 2021 (USD Million)
  • TABLE 15. Others market size, by region, 2022 - 2030 (USD Million)
  • TABLE 16. North America rapid influenza diagnostic tests market size, by country, 2017 - 2021 (USD Million)
  • TABLE 17. North America rapid influenza diagnostic tests market size, by country, 2022 - 2030 (USD Million)
  • TABLE 18. North America rapid influenza diagnostic tests market size, by end-use, 2017 - 2021 (USD Million)
  • TABLE 19. North America rapid influenza diagnostic tests market size, by end-use, 2022 - 2030 (USD Million)
  • TABLE 20. U.S. rapid influenza diagnostic tests market size, by end-use, 2017 - 2021 (USD Million)
  • TABLE 21. U.S. rapid influenza diagnostic tests market size, by end-use, 2022 - 2030 (USD Million)
  • TABLE 22. Canada rapid influenza diagnostic tests market size, by end-use, 2017 - 2021 (USD Million)
  • TABLE 23. Canada rapid influenza diagnostic tests market size, by end-use, 2022 - 2030 (USD Million)
  • TABLE 24. Europe rapid influenza diagnostic tests market size, by country, 2017 - 2021 (USD Million)
  • TABLE 25. Europe rapid influenza diagnostic tests market size, by country, 2022 - 2030 (USD Million)
  • TABLE 26. Europe rapid influenza diagnostic tests market size, by end-use, 2017 - 2021 (USD Million)
  • TABLE 27. Europe rapid influenza diagnostic tests market size, by end-use, 2022 - 2030 (USD Million)
  • TABLE 28. Germany rapid influenza diagnostic tests market size, by end-use, 2017 - 2021 (USD Million)
  • TABLE 29. Germany rapid influenza diagnostic tests market size, by end-use, 2022 - 2030 (USD Million)
  • TABLE 30. UK rapid influenza diagnostic tests market size, by end-use, 2017 - 2021 (USD Million)
  • TABLE 31. UK rapid influenza diagnostic tests market size, by end-use, 2022 - 2030 (USD Million)
  • TABLE 32. France rapid influenza diagnostic tests market size, by end-use, 2017 - 2021 (USD Million)
  • TABLE 33. France rapid influenza diagnostic tests market size, by end-use, 2022 - 2030 (USD Million)
  • TABLE 34. Italy rapid influenza diagnostic tests market size, by end-use, 2017 - 2021 (USD Million)
  • TABLE 35. Italy rapid influenza diagnostic tests market size, by end-use, 2022 - 2030 (USD Million)
  • TABLE 36. Spain rapid influenza diagnostic tests market size, by end-use, 2017 - 2021 (USD Million)
  • TABLE 37. Spain rapid influenza diagnostic tests market size, by end-use, 2022 - 2030 (USD Million)
  • TABLE 38. Asia Pacific rapid influenza diagnostic tests market size, by country, 2017 - 2021 (USD Million)
  • TABLE 39. Asia Pacific rapid influenza diagnostic tests market size, by country, 2022 - 2030 (USD Million)
  • TABLE 40. Asia Pacific rapid influenza diagnostic tests market size, by end-use, 2017 - 2021 (USD Million)
  • TABLE 41. Asia Pacific rapid influenza diagnostic tests market size, by end-use, 2022 - 2030 (USD Million)
  • TABLE 42. China rapid influenza diagnostic tests market size, by end-use, 2017 - 2021 (USD Million)
  • TABLE 43. China rapid influenza diagnostic tests market size, by end-use, 2022 - 2030 (USD Million)
  • TABLE 44. Japan rapid influenza diagnostic tests market size, by end-use, 2017 - 2021 (USD Million)
  • TABLE 45. Japan rapid influenza diagnostic tests market size, by end-use, 2022 - 2030 (USD Million)
  • TABLE 46. India rapid influenza diagnostic tests market size, by end-use, 2017 - 2021 (USD Million)
  • TABLE 47. India rapid influenza diagnostic tests market size, by end-use, 2022 - 2030 (USD Million)
  • TABLE 48. Australia rapid influenza diagnostic tests market size, by end-use, 2017 - 2021 (USD Million)
  • TABLE 49. Australia rapid influenza diagnostic tests market size, by end-use, 2022 - 2030 (USD Million)
  • TABLE 50. South Korea rapid influenza diagnostic tests market size, by end-use, 2017 - 2021 (USD Million)
  • TABLE 51. South Korea rapid influenza diagnostic tests market size, by end-use, 2022 - 2030 (USD Million)
  • TABLE 52. Latin America rapid influenza diagnostic tests market size, by country, 2017 - 2021 (USD Million)
  • TABLE 53. Latin America rapid influenza diagnostic tests market size, by country, 2022 - 2030 (USD Million)
  • TABLE 54. Latin America rapid influenza diagnostic tests market size, by end-use, 2017 - 2021 (USD Million)
  • TABLE 55. Latin America rapid influenza diagnostic tests market size, by end-use, 2022 - 2030 (USD Million)
  • TABLE 56. Brazil rapid influenza diagnostic tests market size, by end-use, 2017 - 2021 (USD Million)
  • TABLE 57. Brazil rapid influenza diagnostic tests market size, by end-use, 2022 - 2030 (USD Million)
  • TABLE 58. Mexico rapid influenza diagnostic tests market size, by end-use, 2017 - 2021 (USD Million)
  • TABLE 59. Mexico rapid influenza diagnostic tests market size, by end-use, 2022 - 2030 (USD Million)
  • TABLE 60. Argentina rapid influenza diagnostic tests market size, by end-use, 2017 - 2021 (USD Million)
  • TABLE 61. Argentina rapid influenza diagnostic tests market size, by end-use, 2022 - 2030 (USD Million)
  • TABLE 62. MEA rapid influenza diagnostic tests market size, by end-use, 2017 - 2021 (USD Million)
  • TABLE 63. MEA rapid influenza diagnostic tests market size, by end-use, 2022 - 2030 (USD Million)
  • TABLE 64. South Africa rapid influenza diagnostic tests market size, by end-use, 2017 - 2021 (USD Million)
  • TABLE 65. South Africa rapid influenza diagnostic tests market size, by end-use, 2022 - 2030 (USD Million)
  • TABLE 66. Saudi Arabia rapid influenza diagnostic tests market size, by end-use, 2017 - 2021 (USD Million)
  • TABLE 67. Saudi Arabia rapid influenza diagnostic tests market size, by end-use, 2022 - 2030 (USD Million)
  • TABLE 68. UAE rapid influenza diagnostic tests market size, by end-use, 2017 - 2021 (USD Million)
  • TABLE 69. UAE rapid influenza diagnostic tests market size, by end-use, 2022 - 2030 (USD Million)

Charts & Figures

  • FIG. 1 Top-down approach (Supply side analysis)
  • FIG. 2 Data Validation
  • FIG. 3 Rapid influenza diagnostic tests market size, 2017 -2030 (USD Million)
  • FIG. 4 Industry segmentation
  • FIG. 5 Global rapid influenza diagnostic tests market, 2017-2030 (USD Million)
  • FIG. 6 Growth potential analysis, by end-use
  • FIG. 7 Porter's analysis
  • FIG. 8 Company matrix analysis, 2021
  • FIG. 9 PESTEL analysis
  • FIG. 10 Key segment trends, by end-use
  • FIG. 11 Key regional trends
  • FIG. 12 Competitive dashboard, 2021
目次
Product Code: 4329

The rapid influenza diagnostic tests (RIDT) market is expected to grow significantly by 2030 owing to increasing prevalence of influenza. In addition, surging necessity for early diagnosis, along with rising popularity of rapid testing, is set to further boost market growth through the forecast period.

Notably, lack of skilled professionals and stringent lockdown regulations imposed during the COVID-19 outbreak posed a threat to market growth However, with the burgeoning number of cases and high risk of exposure to COVID-19 in hospital settings, at-home testing gained massive popularity. Thus, rising consumer interest in at-home testing kits, coupled with soaring demand for telemedicine for influenza infection diagnosis, has positively impacted the product landscape of the rapid influenza diagnostic tests (RIDT) market.

Furthermore, major players in the industry have been focusing on research and development activities to introduce technologically advanced rapid influenza tests. In addition, strategic partnerships and acquisitions have also aided in business expansion.

For instance, in October 2020, Quidel Corporation, a leading manufacturer of diagnostic healthcare products, received EUA (Emergency Use Authorization) from the U.S. FDA (Food and Drug Administration) for marketing its Sofia 2 Flu + SARS Antigen FIA, a rapid point-of-care test used in conjunction with Sofia 2 Fluorescent Immunoassay Analyzer to differentiate nucleocapsid protein antigen from SARS-CoV-2 and influenza A and B via direct nasal (NS) and nasopharyngeal (NP) swab samples in potential COVID-19 patients.

To cite another instance, in March 2021, Abbott, a multinational medical and healthcare devices company, introduced its Alinity m Resp-4-Plex assay that detects COVID-19, influenza A, influenza B, and RSV using only one swab. The innovation, which has received U.S. FDA Emergency Use Authorization, aims to reduce discomfort, and give an efficient four-in-one assay for quick diagnosis.

In another instance, in January 2021, Thermo Fisher Scientific, a prominent supplier in the rapid influenza diagnostic tests (RIDT) market, announced its plans to takeover molecular diagnostic expert Mesa Biotech. Mesa provides gold-standard nucleic acid PCR (polymerase chain reaction) amplification to point-of-care diagnostics for COVID-19, RSV, Influenza A and B, and Strep A.

The rapid influenza diagnostic tests (RIDT) market has been bifurcated in terms of end-use and region. Based on end-use, the RIDT market has been divided into research laboratories, hospitals, diagnostic centers, and others. In 2021, the hospitals segment accounted for over $272 million in revenue and is poised to register substantial gains by 2030. Several factors, including the availability of board-certified skilled doctors, high success rate, faster & more efficient work, and so forth, are slated to fuel segmental growth in the forthcoming years.

In the regional landscape, the Latin America rapid influenza diagnostic tests (RIDT) market garnered a valuation of approximately $82 million in 2021 and is anticipated to grow at a CAGR of over 7.5% through the forecast timeline. Rising prevalence of influenza and growing awareness about influenza infection in countries across the region are likely to support LATAM market expansion in the future.

Table of Contents

Chapter 1 Methodology

  • 1.1 Market definitions
  • 1.2 Base estimates & working
  • 1.3 Forecast calculations
  • 1.4 Data validation
  • 1.5 Data sources
    • 1.5.1 Secondary
      • 1.5.1.1 Paid sources
      • 1.5.1.2 Unpaid sources
    • 1.5.2 Primary

Chapter 2 Executive Summary

  • 2.1 Rapid influenza diagnostic tests industry 360 degree synopsis, 2017 - 2030
    • 2.1.1 Business trends
    • 2.1.2 End-use trends
    • 2.1.3 Regional Trends

Chapter 3 Rapid Influenza Diagnostic Tests Industry Insights

  • 3.1 Industry segmentation
  • 3.2 Industry landscape, 2017 - 2030 (USD Million)
  • 3.3 Industry impact forces
    • 3.3.1 Growth drivers
      • 3.3.1.1 Growing prevalence of influenza
      • 3.3.1.2 Technological advancements
      • 3.3.1.3 Rising demand for early diagnosis and control of influenza
      • 3.3.1.4 Increasing popularity of rapid diagnostic tests
      • 3.3.1.5 Diagnostic advantages in influenza testing
    • 3.3.2 Industry pitfalls & challenges
      • 3.3.2.1 Lack of skilled professionals
      • 3.3.2.2 Stringent regulations
  • 3.4 Growth potential analysis
    • 3.4.1 By end-use
  • 3.5 COVID-19 impact analysis
  • 3.6 Porter's analysis
  • 3.7 Competitive landscape, 2021
    • 3.7.1 Company matrix analysis, 2021
  • 3.8 PESTEL analysis

Chapter 4 Rapid Influenza Diagnostic Tests Market, By End-use

  • 4.1 Key segment trends
  • 4.2 Hospitals
    • 4.2.1 Market size, by region, 2017 - 2030 (USD Million)
  • 4.3 Diagnostics centers,
    • 4.3.1 Market size, by region, 2017 - 2030 (USD Million)
  • 4.4 Research laboratories
    • 4.4.1 Market size, by region, 2017 - 2030 (USD Million)
  • 4.5 Others
    • 4.5.1 Market size, by region, 2017 - 2030 (USD Million)

Chapter 5 Rapid Influenza Diagnostic Tests Market, By Region

  • 5.1 Key regional trends
  • 5.2 North America
    • 5.2.1 Market size, by country, 2017 - 2030 (USD Million)
    • 5.2.2 Market size, by end-use, 2017 - 2030 (USD Million)
    • 5.2.3 U.S.
      • 5.2.3.1 Market size, by end-use, 2017 - 2030 (USD Million)
    • 5.2.4 Canada
      • 5.2.4.1 Market size, by end-use, 2017 - 2030 (USD Million)
  • 5.3 Europe
    • 5.3.1 Market size, by country, 2017 - 2030 (USD Million)
    • 5.3.2 Market size, by end-use, 2017 - 2030 (USD Million)
    • 5.3.3 Germany
      • 5.3.3.1 Market size, by end-use, 2017 - 2030 (USD Million)
    • 5.3.4 UK
      • 5.3.4.1 Market size, by end-use, 2017 - 2030 (USD Million)
    • 5.3.5 France
      • 5.3.5.1 Market size, by end-use, 2017 - 2030 (USD Million)
    • 5.3.6 Italy
      • 5.3.6.1 Market size, by end-use, 2017 - 2030 (USD Million)
    • 5.3.7 Spain
      • 5.3.7.1 Market size, by end-use, 2017 - 2030 (USD Million)
  • 5.4 Asia Pacific
    • 5.4.1 Market size, by country, 2017 - 2030 (USD Million)
    • 5.4.2 Market size, by end-use, 2017 - 2030 (USD Million)
    • 5.4.3 China
      • 5.4.3.1 Market size, by end-use, 2017 - 2030 (USD Million)
    • 5.4.4 Japan
      • 5.4.4.1 Market size, by end-use, 2017 - 2030 (USD Million)
    • 5.4.5 India
      • 5.4.5.1 Market size, by end-use, 2017 - 2030 (USD Million)
    • 5.4.6 Australia
      • 5.4.6.1 Market size, by end-use, 2017 - 2030 (USD Million)
    • 5.4.7 South Korea
      • 5.4.7.1 Market size, by end-use, 2017 - 2030 (USD Million)
  • 5.5 Latin America
    • 5.5.1 Market size, by country, 2017 - 2030 (USD Million)
    • 5.5.2 Market size, by end-use, 2017 - 2030 (USD Million)
    • 5.5.3 Brazil
      • 5.5.3.1 Market size, by end-use, 2017 - 2030 (USD Million)
    • 5.5.4 Mexico
      • 5.5.4.1 Market size, by end-use, 2017 - 2030 (USD Million)
    • 5.5.5 Argentina
      • 5.5.5.1 Market size, by end-use, 2017 - 2030 (USD Million)
  • 5.6 Middle East & Africa
    • 5.6.1 Market size, by country, 2017 - 2030 (USD Million)
    • 5.6.2 Market size, by end-use, 2017 - 2030 (USD Million)
    • 5.6.3 South Africa
      • 5.6.3.1 Market size, by end-use, 2017 - 2030 (USD Million)
    • 5.6.4 Saudi Arabia
      • 5.6.4.1 Market size, by end-use, 2017 - 2030 (USD Million)
    • 5.6.5 UAE
      • 5.6.5.1 Market size, by end-use, 2017 - 2030 (USD Million)

Chapter 6 Company Profiles

  • 6.1 Competitive dashboard, 2021
  • 6.2 F. Hoffmann-La Roche Ltd
    • 6.2.1 Business overview
    • 6.2.2 Financial data
    • 6.2.3 Product landscape
    • 6.2.4 Strategic outlook
    • 6.2.5 SWOT analysis
  • 6.3 Abbott
    • 6.3.1 Business overview
    • 6.3.2 Financial data
    • 6.3.3 Product landscape
    • 6.3.4 Strategic outlook
    • 6.3.5 SWOT analysis
  • 6.4 Becton, Dickinson and Company
    • 6.4.1 Business overview
    • 6.4.2 Financial data
    • 6.4.3 Product landscape
    • 6.4.4 Strategic outlook
    • 6.4.5 SWOT analysis
  • 6.5 Coris BioConcept
    • 6.5.1 Business overview
    • 6.5.2 Financial data
    • 6.5.3 Product landscape
    • 6.5.4 Strategic outlook
    • 6.5.5 SWOT analysis
  • 6.6 DiaSorin SpA
    • 6.6.1 Business overview
    • 6.6.2 Financial data
    • 6.6.3 Product landscape
    • 6.6.4 Strategic outlook
    • 6.6.5 SWOT analysis
  • 6.7 Meridian Bioscience Inc.
    • 6.7.1 Business overview
    • 6.7.2 Financial data
    • 6.7.3 Product landscape
    • 6.7.4 Strategic outlook
    • 6.7.5 SWOT analysis
  • 6.8 Quidel Corporation
    • 6.8.1 Business overview
    • 6.8.2 Financial data
    • 6.8.3 Product landscape
    • 6.8.4 Strategic outlook
    • 6.8.5 SWOT analysis
  • 6.9 Sekisui Diagnostics
    • 6.9.1 Business overview
    • 6.9.2 Financial data
    • 6.9.3 Product landscape
    • 6.9.4 Strategic outlook
    • 6.9.5 SWOT analysis
  • 6.10 Thermo Fischer Scientific Inc.
    • 6.10.1 Business overview
    • 6.10.2 Financial data
    • 6.10.3 Product landscape
    • 6.10.4 Strategic outlook
    • 6.10.5 SWOT analysis
  • 6.11 Hologic Inc.
    • 6.11.1 Business overview
    • 6.11.2 Financial data
    • 6.11.3 Product landscape
    • 6.11.4 Strategic outlook
    • 6.11.5 SWOT analysis